Scholar Rock

55 articles with Scholar Rock

• Scholar Rock to Present at Upcoming Healthcare Conferences - Nov 12, 2020

  11/12/2020

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will participate in the following upcoming virtual investor conferences

• Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress

  11/9/2020

  Positive interim analysis data from the TOPAZ Phase 2 trial demonstrated proof-of-concept for apitegromab (SRK-015) in patients with Type 2 and Type 3 Spinal Muscular Atrophy

• Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

  11/2/2020

  Scholar Rock Holding Corporation announced the closing of its underwritten public offering of 3,717,948 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,179,487 shares of its common stock at an exercise price of $0.0001 per share.

• Scholar Rock Announces Pricing of Public Offering of Common Stock and Prefunded Warrants - Oct 29, 2020

  10/29/2020

  Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.

• Scholar Rock Announces Proposed Public Offering of Common Stock

  10/27/2020

  Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it intends to offer and sell in an underwritten public offering $150,000,000 of shares of its common stock. In addition, Scholar Rock intends to grant the underwriters a 30-day option to purchase up to an addit

• Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy

  10/27/2020

  Motor function improvements were observed for all three SRK-015 treatment cohorts in the primary efficacy endpoints (Hammersmith scale scores) at six-months; top-line data from the 12-month treatment period are anticipated in 2Q21

• Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress

  9/30/2020

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) 2020 Virtual Congress. The SRK-015 clinical development poster will showcase previously presented data from the Phase 1 healthy volunteer trial, as well as baselin

• Scholar Rock Announces First Patient Dosed in Part A2 of DRAGON Phase 1 Proof-of-Concept Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy

  9/9/2020

  - Patients with locally advanced or metastatic solid tumors are being enrolled and dosed with SRK-181 in combination with anti-PD-(L)1 therapy in Part A2 of the DRAGON Phase 1 clinical trial - An update on Part A dose escalation is expected in the fourth quarter of 2020; Part B efficacy and safety data from the trial anticipated starting in 2021

• Scholar Rock to Present at Upcoming Healthcare Conferences

  9/2/2020

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming virtual investor conferences: Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 3:10 pm ET. Citi’s 15 th Annual BioPharma Virtua

• Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015

  8/27/2020

  Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,751,413 providing product protection for SRK-015, including composition of matter and methods of use, with an expiry of January 2037. “We are at the forefro

• Scholar Rock Announces that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy

  8/13/2020

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for SRK-015 for the treatment of Spinal Muscular Atrophy (SMA), a progressive, rare genetic disease that leads to motor function

• Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress

  8/7/2020

  On track to report interim efficacy and safety results from TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) in 4Q20 - Enrollment expected to advance to combination treatment of SRK-181 and an approved anti-PD-(L)1 therapy in Part A of DRAGON Phase 1 clinical trial in 3Q20; update on dose escalation expected in 4Q20 - Appointed Tony Kingsley as President and CEO and Ted Myles as CFO and He

• Scholar Rock to Present at the 2020 Wedbush PacGrow Healthcare Conference

  8/5/2020

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 9:45 am ET.

• Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020

  8/3/2020

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it will host a live conference call and webcast at 8:00am ET on Friday, August 7, 2020 to discuss second quarter 2020 financial results and business progress, as well as provide an introduction to the newest members of its manage

• Scholar Rock Appoints Edward (Ted) Myles as Chief Financial Officer and Head of Business Operations

  7/16/2020

  - Financial and operational leader brings deep expertise from across clinical and commercial stage biopharmaceutical companies

• Scholar Rock Appoints Tony Kingsley as President and CEO

  7/14/2020

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced the appointment of Tony Kingsley as president and chief executive officer, effective August 1, 2020.

• Scholar Rock to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

  6/16/2020

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 9:00 am ET.

• Scholar Rock to Present at the Jefferies 2020 Virtual Global Healthcare Conference

  5/27/2020

  Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 8:30 am ET.

• Scholar Rock Appoints Tony Kingsley to Its Board of Directors

  5/21/2020

  Proven leader with extensive operational and commercial experience joins expanded Board

• Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference

  5/18/2020

  Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a poster presentation as part of the 2020 American Academy of Neurology Science Highlights virtual platform. The presentation will include baseline demographics as well as preliminary pharmacokinetic and biomarker data from the TOPAZ